Breast Cancer Risk in Ataxia Telangiectasia (AT) Heterozygotes: Haplotype Study in French AT Families

Overview

Journal Br J Cancer

Specialty Oncology

Date 1999 Jun 11

PMID 10362113

Citations 26

Authors

N Janin

N Andrieu

K Ossian

A Lauge

M F Croquette

C Griscelli

M Debre

A Aurias

D Stoppa-Lyonnet

Affiliations

Soon will be listed here.

Abstract

Epidemiological studies in ataxia telangiectasia (AT) families have suggested that AT heterozygotes could have an increased cancer risk, especially breast cancer (BC) in women. It has also been suggested that an increased sensibility of AT heterozygotes to the effect of ionizing radiation could be responsible for the increased BC risk. BC relative risk (RR) estimation in AT heterozygotes within families ascertained through AT children is presented here. Family data collected included demographic characteristics, occurrence of cancers, past radiation exposures and blood samples. DNA samples were studied using seven ATM linked microsatellites markers allowing AT haplotypes reconstitution. The relative risk of BC was assessed using French estimated incidence rates. A significant increase risk of BC is found among obligate ATM heterozygotes with a point estimate of 3.32 (P = 0.002). BC relative risk calculated according to age is significantly increased among the obligate ATM heterozygotes female relatives with an age < or = 44 years (RR = 4.55, P = 0.005). The BC relative risk is statistically borderline among the obligate ATM heterozygote female relatives with an age > or = 45 years (RR = 2.48, P = 0.08). The estimated BC relative risk among ATM heterozygotes is consistent with previously published data. However, the increased risk is only a little higher than classical reproductive risk factors and similar to the risk associated with a first-degree relative affected by BC.

Citing Articles

Breast tumors from ATM pathogenic variant carriers display a specific genome-wide DNA methylation profile.

Viart N, Renault A, Eon-Marchais S, Jiao Y, Fuhrmann L, El Houdigui S Breast Cancer Res. 2025; 27(1):36.

PMID: 40069712 PMC: 11899765. DOI: 10.1186/s13058-025-01988-w.

Safety of the Breast Cancer Adjuvant Radiotherapy in Ataxia-Telangiectasia Mutated Variant Carriers.

Bensenane R, Beddok A, Lesueur F, Fourquet A, Warcoin M, Le Mentec M Cancers (Basel). 2024; 16(7).

PMID: 38611095 PMC: 11010818. DOI: 10.3390/cancers16071417.

Evaluation of Ataxia-Telangiectasia Mutated IVS10 Mutation in Breast Cancer Along with Clinicopathological Parameters.

Ahuja S, Aneja H, Yadav A, Ranga S, Chintamani , Paul J J Midlife Health. 2024; 14(4):272-279.

PMID: 38504739 PMC: 10946688. DOI: 10.4103/jmh.jmh_71_23.

First international workshop of the ATM and cancer risk group (4-5 December 2019).

Lesueur F, Easton D, Renault A, Tavtigian S, Bernstein J, Kote-Jarai Z Fam Cancer. 2021; 21(2):211-227.

PMID: 34125377 PMC: 9969796. DOI: 10.1007/s10689-021-00248-y.

Next generation DNA sequencing of atypical choroid plexus papilloma of brain: Identification of novel mutations in a female patient by Ion Proton.

Taher M, Ali Hassan A, Saeed M, Jastania R, Nageeti T, Alkhalidi H Oncol Lett. 2019; 18(5):5063-5076.

PMID: 31612017 PMC: 6781611. DOI: 10.3892/ol.2019.10882.

References

Coleman M, Douglas A, Hermon C, Peto J . Cohort study analysis with a FORTRAN computer program. Int J Epidemiol. 1986; 15(1):134-7. DOI: 10.1093/ije/15.1.134. View

Shayeghi M, Seal S, Regan J, Collins N, Barfoot R, Rahman N . Heterozygosity for mutations in the ataxia telangiectasia gene is not a major cause of radiotherapy complications in breast cancer patients. Br J Cancer. 1998; 78(7):922-7. PMC: 2063134. DOI: 10.1038/bjc.1998.602. View

Pippard E, Hall A, Barker D, Bridges B . Cancer in homozygotes and heterozygotes of ataxia-telangiectasia and xeroderma pigmentosum in Britain. Cancer Res. 1988; 48(10):2929-32. View

Morrell D, Chase C, Swift M . Cancers in 44 families with ataxia-telangiectasia. Cancer Genet Cytogenet. 1990; 50(1):119-23. DOI: 10.1016/0165-4608(90)90245-6. View

Borresen A, Andersen T, Tretli S, Heiberg A, Moller P . Breast cancer and other cancers in Norwegian families with ataxia-telangiectasia. Genes Chromosomes Cancer. 1990; 2(4):339-40. DOI: 10.1002/gcc.2870020412. View

Swift M, Morrell D, Massey R, Chase C . Incidence of cancer in 161 families affected by ataxia-telangiectasia. N Engl J Med. 1991; 325(26):1831-6. DOI: 10.1056/NEJM199112263252602. View

Kelsey J, Horn-Ross P . Breast cancer: magnitude of the problem and descriptive epidemiology. Epidemiol Rev. 1993; 15(1):7-16. DOI: 10.1093/oxfordjournals.epirev.a036118. View

Theis B, Boyd N, Lockwood G, Tritchler D . Accuracy of family cancer history in breast cancer patients. Eur J Cancer Prev. 1994; 3(4):321-7. DOI: 10.1097/00008469-199407000-00004. View

Easton D . Cancer risks in A-T heterozygotes. Int J Radiat Biol. 1994; 66(6 Suppl):S177-82. DOI: 10.1080/09553009414552011. View

10.

Aitken J, Bain C, Ward M, Siskind V, MACLENNAN R . How accurate is self-reported family history of colorectal cancer?. Am J Epidemiol. 1995; 141(9):863-71. DOI: 10.1093/oxfordjournals.aje.a117522. View

11.

Savitsky K, Bar-Shira A, Gilad S, Rotman G, Ziv Y, Vanagaite L . A single ataxia telangiectasia gene with a product similar to PI-3 kinase. Science. 1995; 268(5218):1749-53. DOI: 10.1126/science.7792600. View

12.

Athma P, Rappaport R, Swift M . Molecular genotyping shows that ataxia-telangiectasia heterozygotes are predisposed to breast cancer. Cancer Genet Cytogenet. 1996; 92(2):130-4. DOI: 10.1016/s0165-4608(96)00328-7. View

13.

Bishop D, Hopper J . AT-tributable risks?. Nat Genet. 1997; 15(3):226. DOI: 10.1038/ng0397-226. View

14.

Fitzgerald M, Bean J, Hegde S, Unsal H, MacDonald D, Harkin D . Heterozygous ATM mutations do not contribute to early onset of breast cancer. Nat Genet. 1997; 15(3):307-10. DOI: 10.1038/ng0397-307. View

15.

Laake K, Odegard A, Andersen T, Bukholm I, Karesen R, Nesland J . Loss of heterozygosity at 11q23.1 in breast carcinomas: indication for involvement of a gene distal and close to ATM. Genes Chromosomes Cancer. 1997; 18(3):175-80. View

16.

Bebb G, Glickman B, Gelmon K, Gatti R . "AT risk" for breast cancer. Lancet. 1997; 349(9068):1784-5. DOI: 10.1016/S0140-6736(05)61687-X. View

17.

Appleby J, Barber J, Levine E, Varley J, Taylor A, Stankovic T . Absence of mutations in the ATM gene in breast cancer patients with severe responses to radiotherapy. Br J Cancer. 1997; 76(12):1546-9. PMC: 2228198. DOI: 10.1038/bjc.1997.593. View

18.

Stankovic T, Kidd A, Sutcliffe A, McGuire G, Robinson P, Weber P . ATM mutations and phenotypes in ataxia-telangiectasia families in the British Isles: expression of mutant ATM and the risk of leukemia, lymphoma, and breast cancer. Am J Hum Genet. 1998; 62(2):334-45. PMC: 1376883. DOI: 10.1086/301706. View

19.

Swift M, Reitnauer P, Morrell D, Chase C . Breast and other cancers in families with ataxia-telangiectasia. N Engl J Med. 1987; 316(21):1289-94. DOI: 10.1056/NEJM198705213162101. View